Chetan Pujara compensation by year
SpyGlass Pharma Summary Compensation Table · the one fiscal year held| Component | FY2025 |
|---|---|
| Salary | $355,250 |
| Bonus | $0 |
| Stock awards | $0 |
| Option awards | $1,049,292 |
| Non-equity incentive | $126,289 |
| Pension and deferred compensation | $0 |
| All other | $9,521 |
| Total | $1,539,952 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: SpyGlass Pharma, Inc. 10-K filed March 26, 2026, accession 0001778922-26-000020, and prior-year filings.
How this page was built: the SpyGlass Pharma, Inc. filed document, accession 0001778922-26-000020. Every figure is read from that document and cited to the page and table it appears in. Filed March 26, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 31,397 | — | $2.87 |
| Option | 153,219 | — | $2.18 |
| Option | 34,798 | — | $7.11 |
Per the Outstanding Equity Awards at Fiscal Year-End table in SpyGlass Pharma, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
SpyGlass Pharma’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Patrick Mooney | Chief Executive Officer | $3,322,711 |
| Malik Kahook | President, Chief Medical Officer and Executive Chair | $2,484,469 |
| Chetan Pujara · this page | Chief Research & Development Officer | $1,539,952 |
The full SpyGlass Pharma compensation record
free company briefThis page is one person within SpyGlass Pharma's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are SpyGlass Pharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.